Work at Axcynsis Therapeutics Pte. Ltd. has led to the creation of antibody-drug conjugates (ADCs) comprising antibodies covalently linked to ecteinascidin and lurbinectedin derivatives through a linker; they are reported to be useful for the treatment of cancer.